JP2018513177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513177A5 JP2018513177A5 JP2017555270A JP2017555270A JP2018513177A5 JP 2018513177 A5 JP2018513177 A5 JP 2018513177A5 JP 2017555270 A JP2017555270 A JP 2017555270A JP 2017555270 A JP2017555270 A JP 2017555270A JP 2018513177 A5 JP2018513177 A5 JP 2018513177A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- pyridin
- carboxamide
- thiazole
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, carboxyl Chemical group 0.000 claims description 607
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 82
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims description 76
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims description 69
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 34
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 30
- PNGWJQONBMCVTJ-UHFFFAOYSA-N S1C=NC(=C1)C(=O)NC(O)=O Chemical compound S1C=NC(=C1)C(=O)NC(O)=O PNGWJQONBMCVTJ-UHFFFAOYSA-N 0.000 claims description 28
- WUAXASOCLCTWRX-UHFFFAOYSA-N furan-2-carbonylcarbamic acid Chemical compound OC(=O)NC(=O)C1=CC=CO1 WUAXASOCLCTWRX-UHFFFAOYSA-N 0.000 claims description 28
- 125000001931 aliphatic group Chemical group 0.000 claims description 27
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 claims description 26
- 125000001188 haloalkyl group Chemical group 0.000 claims description 23
- 229910019142 PO4 Inorganic materials 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 239000010452 phosphate Substances 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 16
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 239000012458 free base Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000000335 thiazolyl group Chemical group 0.000 claims description 9
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims description 8
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 8
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- YJTRFJIAMAMBHB-UHFFFAOYSA-N 3-[1-(3,3-difluorocyclobutyl)-3-pyridin-2-ylpyrazol-4-yl]-2-(1H-pyrazol-4-yl)-2H-1,3-thiazole Chemical compound FC1(CC(C1)N1N=C(C(=C1)N1C(SC=C1)C=1C=NNC1)C1=NC=CC=C1)F YJTRFJIAMAMBHB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- MBTOOKBKBYXTCE-UHFFFAOYSA-L disodium;methyl phosphate Chemical compound [Na+].[Na+].COP([O-])([O-])=O MBTOOKBKBYXTCE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- CAAULPUQFIIOTL-UHFFFAOYSA-M methyl hydrogen phosphate Chemical compound COP(O)([O-])=O CAAULPUQFIIOTL-UHFFFAOYSA-M 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- QETMRHQTVLFIPW-UHFFFAOYSA-N (1-methylcyclopropyl) 4-[4-[(1-methyl-3-pyridin-2-ylpyrazol-4-yl)carbamoyl]-1,3-thiazol-2-yl]pyrazole-1-carboxylate Chemical compound CN1N=C(C(=C1)NC(=O)C=1N=C(SC=1)C=1C=NN(C=1)C(=O)OC1(CC1)C)C1=NC=CC=C1 QETMRHQTVLFIPW-UHFFFAOYSA-N 0.000 claims description 2
- GDBALSNVRLWFEX-UHFFFAOYSA-N (1-methylcyclopropyl) 4-[5-[[1-(2-methoxyethyl)-3-pyridin-2-ylpyrazol-4-yl]carbamoyl]furan-2-yl]pyrazole-1-carboxylate Chemical compound COCCN1N=C(C(=C1)NC(=O)C1=CC=C(O1)C=1C=NN(C=1)C(=O)OC1(CC1)C)C1=NC=CC=C1 GDBALSNVRLWFEX-UHFFFAOYSA-N 0.000 claims description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- REZCJQIIJVPKAF-UHFFFAOYSA-N C1(CC1)CN1N=CC(=C1)C1OC=CN1C=1C(=NN(C1)C)C1=NC=CC=C1 Chemical compound C1(CC1)CN1N=CC(=C1)C1OC=CN1C=1C(=NN(C1)C)C1=NC=CC=C1 REZCJQIIJVPKAF-UHFFFAOYSA-N 0.000 claims description 2
- TZTVKIVBDYAXKS-UHFFFAOYSA-N CC1=C(C=NN1)C2=CC=C(O2)C(=O)N(C3=CN(N=C3C4=CC=CC=N4)CCOC)C(=O)O Chemical compound CC1=C(C=NN1)C2=CC=C(O2)C(=O)N(C3=CN(N=C3C4=CC=CC=N4)CCOC)C(=O)O TZTVKIVBDYAXKS-UHFFFAOYSA-N 0.000 claims description 2
- TXIXBWPJMNOQLG-UHFFFAOYSA-M CN(C=C1NC(C2=CSC(C(C=N3)=CN3OP([O-])(OC)=O)=N2)=O)N=C1C1=NC=CC=C1.[Na+] Chemical compound CN(C=C1NC(C2=CSC(C(C=N3)=CN3OP([O-])(OC)=O)=N2)=O)N=C1C1=NC=CC=C1.[Na+] TXIXBWPJMNOQLG-UHFFFAOYSA-M 0.000 claims description 2
- QQVAAOUFNUFDPL-UHFFFAOYSA-M CN(C=C1NC(C2=CSC(C3=CN(COP([O-])=O)N=C3)=N2)=O)N=C1C1=NC=CC=C1.[Na+] Chemical class CN(C=C1NC(C2=CSC(C3=CN(COP([O-])=O)N=C3)=N2)=O)N=C1C1=NC=CC=C1.[Na+] QQVAAOUFNUFDPL-UHFFFAOYSA-M 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 2
- VCXTZIGRKPMUMN-UHFFFAOYSA-M P(=O)(ON1N=CC(=C1)C=1OC(=CC1)C(NC=1C(=NN(C1)CCOC)C1=NC=CC=C1)=O)(OC)[O-].[Na+] Chemical compound P(=O)(ON1N=CC(=C1)C=1OC(=CC1)C(NC=1C(=NN(C1)CCOC)C1=NC=CC=C1)=O)(OC)[O-].[Na+] VCXTZIGRKPMUMN-UHFFFAOYSA-M 0.000 claims description 2
- SKDDEHAVBWKSCR-UHFFFAOYSA-M P(=O)(ON1N=CC(=C1)C=1OC(=CC1)C(NC=1C(=NN(C1)CCOCC)C1=NC=CC=C1)=O)(OC)[O-].[Na+] Chemical compound P(=O)(ON1N=CC(=C1)C=1OC(=CC1)C(NC=1C(=NN(C1)CCOCC)C1=NC=CC=C1)=O)(OC)[O-].[Na+] SKDDEHAVBWKSCR-UHFFFAOYSA-M 0.000 claims description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- XHVMAHLWCMJJRT-UHFFFAOYSA-N [1-(3-ethoxycyclobutyl)-6,7-dihydro-5H-pyrazolo[4,3-b]pyridin-4-yl]-[2-(1H-pyrazol-4-yl)-1,3-thiazol-4-yl]methanone 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC1CC(C1)n1ncc2N(CCCc12)C(=O)c1csc(n1)-c1cn[nH]c1 XHVMAHLWCMJJRT-UHFFFAOYSA-N 0.000 claims description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- RAKINNFKPYCWIS-UHFFFAOYSA-N ditert-butyl [4-[5-[[1-(2-methoxyethyl)-3-pyridin-2-ylpyrazol-4-yl]carbamoyl]furan-2-yl]pyrazol-1-yl]methyl phosphate Chemical compound P(=O)(OC(C)(C)C)(OC(C)(C)C)OCN1N=CC(=C1)C=1OC(=CC=1)C(NC=1C(=NN(C=1)CCOC)C1=NC=CC=C1)=O RAKINNFKPYCWIS-UHFFFAOYSA-N 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- XXPKIDAWGVKUBD-UHFFFAOYSA-N formaldehyde;2,2,2-trifluoroacetic acid Chemical compound O=C.OC(=O)C(F)(F)F XXPKIDAWGVKUBD-UHFFFAOYSA-N 0.000 claims description 2
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 2
- IGSSNLHDFIYOIL-UHFFFAOYSA-N furan-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC=CO1 IGSSNLHDFIYOIL-UHFFFAOYSA-N 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 230000019100 sperm motility Effects 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- DKVHSIGYVOGGES-UHFFFAOYSA-N tert-butyl 4-[5-[[1-(2-ethoxyethyl)-3-pyridin-2-ylpyrazol-4-yl]carbamoyl]furan-2-yl]pyrazole-1-carboxylate Chemical compound C(C)OCCN1N=C(C(=C1)NC(=O)C1=CC=C(O1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=NC=CC=C1 DKVHSIGYVOGGES-UHFFFAOYSA-N 0.000 claims description 2
- LUEILWKCNRMZKG-UHFFFAOYSA-N tert-butyl [4-[5-[[1-(2-methoxyethyl)-3-pyridin-2-ylpyrazol-4-yl]carbamoyl]furan-2-yl]pyrazol-1-yl]methyl hydrogen phosphate Chemical compound P(=O)(OC(C)(C)C)(OCN1N=CC(=C1)C=1OC(=CC=1)C(NC=1C(=NN(C=1)CCOC)C1=NC=CC=C1)=O)O LUEILWKCNRMZKG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- IMQYCAOLMXPFRY-UHFFFAOYSA-N n-(1h-pyrazol-4-yl)-1,3-thiazole-4-carboxamide Chemical compound C=1SC=NC=1C(=O)NC=1C=NNC=1 IMQYCAOLMXPFRY-UHFFFAOYSA-N 0.000 claims 1
- OSYWKBOVEOEMQD-UHFFFAOYSA-N n-(1h-pyrazol-4-yl)furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC=1C=NNC=1 OSYWKBOVEOEMQD-UHFFFAOYSA-N 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 description 13
- 235000021317 phosphate Nutrition 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 6
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 3
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 3
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 3
- 0 CCCC(Nc1c[n](*)nc1C)=O Chemical compound CCCC(Nc1c[n](*)nc1C)=O 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LUGGQBCOTDQVME-OUPQRBNQSA-N C=C/C=C\C=C/N Chemical compound C=C/C=C\C=C/N LUGGQBCOTDQVME-OUPQRBNQSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151274P | 2015-04-22 | 2015-04-22 | |
| US62/151,274 | 2015-04-22 | ||
| PCT/US2016/028957 WO2016172560A1 (en) | 2015-04-22 | 2016-04-22 | Pyrazole compounds and method for making and using the compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173954A Division JP7050879B2 (ja) | 2015-04-22 | 2020-10-15 | ピラゾール化合物ならびにこの化合物を作製および使用するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513177A JP2018513177A (ja) | 2018-05-24 |
| JP2018513177A5 true JP2018513177A5 (enExample) | 2019-05-30 |
| JP6835739B2 JP6835739B2 (ja) | 2021-02-24 |
Family
ID=55858915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555270A Active JP6835739B2 (ja) | 2015-04-22 | 2016-04-22 | ピラゾール化合物ならびにこの化合物を作製および使用するための方法 |
| JP2020173954A Active JP7050879B2 (ja) | 2015-04-22 | 2020-10-15 | ピラゾール化合物ならびにこの化合物を作製および使用するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173954A Active JP7050879B2 (ja) | 2015-04-22 | 2020-10-15 | ピラゾール化合物ならびにこの化合物を作製および使用するための方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9982000B2 (enExample) |
| EP (1) | EP3286181B1 (enExample) |
| JP (2) | JP6835739B2 (enExample) |
| KR (1) | KR102677905B1 (enExample) |
| CN (2) | CN107438603B (enExample) |
| AU (1) | AU2016252869B2 (enExample) |
| BR (1) | BR112017022349B1 (enExample) |
| CA (1) | CA2980800C (enExample) |
| CL (1) | CL2017002640A1 (enExample) |
| CO (1) | CO2017010583A2 (enExample) |
| CY (1) | CY1124422T1 (enExample) |
| DK (1) | DK3286181T3 (enExample) |
| EA (1) | EA039043B1 (enExample) |
| ES (1) | ES2861351T3 (enExample) |
| HR (1) | HRP20210433T1 (enExample) |
| HU (1) | HUE054042T2 (enExample) |
| IL (1) | IL254615B (enExample) |
| LT (1) | LT3286181T (enExample) |
| MX (1) | MX380940B (enExample) |
| MY (1) | MY189941A (enExample) |
| PE (1) | PE20180118A1 (enExample) |
| PH (1) | PH12017501925A1 (enExample) |
| PL (1) | PL3286181T3 (enExample) |
| PT (1) | PT3286181T (enExample) |
| RS (1) | RS61636B1 (enExample) |
| SG (2) | SG10201912656SA (enExample) |
| SI (1) | SI3286181T1 (enExample) |
| SM (1) | SMT202100186T1 (enExample) |
| WO (1) | WO2016172560A1 (enExample) |
| ZA (1) | ZA201706545B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3286181T3 (da) * | 2015-04-22 | 2021-04-06 | Rigel Pharmaceuticals Inc | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| CN110234637B (zh) | 2016-10-26 | 2022-11-01 | 里格尔药品股份有限公司 | 用作irak抑制剂的吡唑酰胺化合物 |
| CN110099899B (zh) * | 2016-10-26 | 2024-01-02 | 里格尔药品股份有限公司 | 用作irak抑制剂的噁唑衍生物及其制备方法 |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| JP7167069B2 (ja) * | 2017-06-29 | 2022-11-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害剤ならびに作製および使用のための方法 |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN107857758B (zh) * | 2017-12-31 | 2018-08-24 | 广东莱恩医药研究院有限公司 | 一种酰胺类化合物及其作为hsp90抑制剂和抗肿瘤药物的应用 |
| CN107987063A (zh) * | 2017-12-31 | 2018-05-04 | 窦玉玲 | 一种hsp90抑制剂及其在抗肿瘤药物的应用 |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| KR20210028144A (ko) * | 2018-04-06 | 2021-03-11 | 블랙 벨트 티엑스 리미티드 | Atf6 저해제 및 그의 용도 |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CA3108065C (en) | 2018-07-31 | 2025-10-07 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| CN110862375B (zh) * | 2018-08-27 | 2022-10-25 | 深圳铂立健医药有限公司 | 吡唑化合物及其药物组合物和应用 |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4009974A1 (en) | 2019-08-08 | 2022-06-15 | Rigel Pharmaceuticals, Inc. | Compounds and method for treating cytokine release syndrome |
| JP2022545542A (ja) * | 2019-08-30 | 2022-10-27 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法 |
| KR20220087464A (ko) | 2019-10-09 | 2022-06-24 | 프락시스 바이오테크 엘엘씨 | Atf6 조정제 및 그의 용도 |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| WO2022187303A1 (en) * | 2021-03-03 | 2022-09-09 | Rigel Pharmaceuticals, Inc. | A method for treating a disease or condition using a pyrazole compound or formulation thereof |
| EP4308115A4 (en) * | 2021-03-17 | 2025-01-22 | Merck Sharp & Dohme LLC | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| KR20240016323A (ko) * | 2021-06-01 | 2024-02-06 | 리얼타 라이프 사이언시즈, 인크. | 펩티드 및 사용 방법 |
| EP4399208A4 (en) * | 2021-09-08 | 2025-07-16 | Rigel Pharmaceuticals Inc | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE CONDITIONS ASSOCIATED WITH RESPIRATORY VIRUS INFECTION |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| ES3075943T3 (en) * | 2022-03-23 | 2026-08-10 | Rigel Pharmaceuticals Inc | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| WO2024011116A2 (en) * | 2022-07-07 | 2024-01-11 | Dana-Farber Cancer Institute, Inc. | Potent and selective irreversible inhibitors of irak1 |
| CN117209489B (zh) * | 2023-05-30 | 2024-07-26 | 杭州邦顺制药有限公司 | Irak激酶抑制剂 |
| WO2025111251A1 (en) * | 2023-11-20 | 2025-05-30 | Exelixis, Inc. | Compounds that inhibit polo-like kinase 4 |
| CN121270516A (zh) * | 2024-07-03 | 2026-01-06 | 科辉智药(深圳)新药研究中心有限公司 | 一种irak抑制剂化合物的晶型及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003287965A1 (en) * | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2006070202A1 (en) * | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
| EP1836188A1 (en) * | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| SI2206707T1 (sl) * | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| US8987309B2 (en) | 2009-04-17 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles |
| EP2243481A1 (en) | 2009-04-24 | 2010-10-27 | PamGene B.V. | Irak kinase family as novel drug target for Alzheimer |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| WO2011043771A1 (en) | 2009-10-07 | 2011-04-14 | Nitto Denko Corporation | Narrow band excitation light source for fluorescence sensing system |
| CA2794801C (en) | 2010-04-07 | 2019-01-15 | F. Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| WO2012072685A1 (en) | 2010-12-02 | 2012-06-07 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Irak-related interventions and diagnosis |
| HUE029617T2 (en) | 2010-12-20 | 2017-03-28 | Merck Serono Sa | Indazolyl triazole derivatives as IRAK inhibitors |
| EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN103347873A (zh) * | 2011-02-09 | 2013-10-09 | 日产化学工业株式会社 | 吡唑衍生物和有害生物防除剂 |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| TW201728592A (zh) | 2012-01-10 | 2017-08-16 | 林伯士艾瑞斯公司 | Ｉｒａｋ抑制劑及其用途 |
| WO2014048939A1 (en) * | 2012-09-26 | 2014-04-03 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| JP6483624B2 (ja) | 2013-02-07 | 2019-03-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピリダジノン−アミド誘導体 |
| ES2639717T3 (es) | 2013-02-07 | 2017-10-30 | Merck Patent Gmbh | Derivados de piridazinona macrocíclicos |
| ES2728403T3 (es) | 2014-01-09 | 2019-10-24 | Merck Patent Gmbh | Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK |
| LT3221306T (lt) | 2014-11-20 | 2020-03-10 | Merck Patent Gmbh | Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas |
| DK3286181T3 (da) | 2015-04-22 | 2021-04-06 | Rigel Pharmaceuticals Inc | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne |
| HK1256242A1 (zh) * | 2015-08-04 | 2019-09-20 | Rigel Pharmaceuticals, Inc. | 吲哚化合物以及制备和使用该化合物的方法 |
-
2016
- 2016-04-22 DK DK16719191.5T patent/DK3286181T3/da active
- 2016-04-22 LT LTEP16719191.5T patent/LT3286181T/lt unknown
- 2016-04-22 HR HRP20210433TT patent/HRP20210433T1/hr unknown
- 2016-04-22 EP EP16719191.5A patent/EP3286181B1/en active Active
- 2016-04-22 BR BR112017022349-0A patent/BR112017022349B1/pt active IP Right Grant
- 2016-04-22 SG SG10201912656SA patent/SG10201912656SA/en unknown
- 2016-04-22 CA CA2980800A patent/CA2980800C/en active Active
- 2016-04-22 SI SI201631128T patent/SI3286181T1/sl unknown
- 2016-04-22 WO PCT/US2016/028957 patent/WO2016172560A1/en not_active Ceased
- 2016-04-22 ES ES16719191T patent/ES2861351T3/es active Active
- 2016-04-22 MX MX2017013413A patent/MX380940B/es unknown
- 2016-04-22 SG SG11201707752SA patent/SG11201707752SA/en unknown
- 2016-04-22 JP JP2017555270A patent/JP6835739B2/ja active Active
- 2016-04-22 CN CN201680021522.7A patent/CN107438603B/zh active Active
- 2016-04-22 HU HUE16719191A patent/HUE054042T2/hu unknown
- 2016-04-22 KR KR1020177031696A patent/KR102677905B1/ko active Active
- 2016-04-22 EA EA201791927A patent/EA039043B1/ru unknown
- 2016-04-22 CN CN202110865696.4A patent/CN113750094A/zh active Pending
- 2016-04-22 PE PE2017002190A patent/PE20180118A1/es unknown
- 2016-04-22 SM SM20210186T patent/SMT202100186T1/it unknown
- 2016-04-22 PL PL16719191T patent/PL3286181T3/pl unknown
- 2016-04-22 US US15/136,508 patent/US9982000B2/en active Active
- 2016-04-22 RS RS20210394A patent/RS61636B1/sr unknown
- 2016-04-22 MY MYPI2017001562A patent/MY189941A/en unknown
- 2016-04-22 AU AU2016252869A patent/AU2016252869B2/en active Active
- 2016-04-22 PT PT167191915T patent/PT3286181T/pt unknown
-
2017
- 2017-09-24 IL IL254615A patent/IL254615B/en unknown
- 2017-09-28 ZA ZA2017/06545A patent/ZA201706545B/en unknown
- 2017-10-17 CL CL2017002640A patent/CL2017002640A1/es unknown
- 2017-10-17 CO CONC2017/0010583A patent/CO2017010583A2/es unknown
- 2017-10-20 PH PH12017501925A patent/PH12017501925A1/en unknown
-
2018
- 2018-03-22 US US15/928,335 patent/US10208074B2/en active Active
- 2018-03-23 US US15/934,692 patent/US10208075B2/en active Active
-
2019
- 2019-01-28 US US16/259,685 patent/US11370808B2/en active Active
-
2020
- 2020-10-15 JP JP2020173954A patent/JP7050879B2/ja active Active
-
2021
- 2021-04-07 CY CY20211100301T patent/CY1124422T1/el unknown
-
2022
- 2022-05-18 US US17/747,342 patent/US20220289776A1/en not_active Abandoned
-
2024
- 2024-11-27 US US18/963,039 patent/US20250326778A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021020924A5 (enExample) | ||
| HRP20210433T1 (hr) | Spojevi pirazola i postupak za dobivanje i upotrebu spojeva | |
| US6699865B2 (en) | Pyrazole compositions useful as inhibitors of ERK | |
| ES2555491T3 (es) | Composiciones y métodos para la inhibición de la ruta de JAK | |
| US10059705B2 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| US20030087922A1 (en) | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | |
| AU2026200338A1 (en) | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereof | |
| US9415047B2 (en) | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | |
| HK1251561B (en) | Pyrazole compounds and method for making and using the compounds | |
| TW202440076A (zh) | 阿維菌素衍生物 | |
| NZ735761B2 (en) | Pyrazole compounds and method for making and using the compounds |